Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report
Mesalamine-containing products are often a first-line treatment for ulcerative colitis. Severe adverse reactions to these products, including cardiovascular toxicity, are rarely seen in pediatric patients. We present a case of a 16-year-old boy with ulcerative colitis treated with Asacol, a mesalami...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Case Reports in Pediatrics |
| Online Access: | http://dx.doi.org/10.1155/2011/524364 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400909704986624 |
|---|---|
| author | Elimarys Perez-Colon Gul H. Dadlani Ivan Wilmot Michelle Miller |
| author_facet | Elimarys Perez-Colon Gul H. Dadlani Ivan Wilmot Michelle Miller |
| author_sort | Elimarys Perez-Colon |
| collection | DOAJ |
| description | Mesalamine-containing products are often a first-line treatment for ulcerative colitis. Severe adverse reactions to these products, including cardiovascular toxicity, are rarely seen in pediatric patients. We present a case of a 16-year-old boy with ulcerative colitis treated with Asacol, a mesalamine-containing product, who developed sudden onset chest pain after four weeks on therapy. Serial electrocardiograms showed nonspecific ST segment changes, an echocardiogram showed mildly decreased left ventricular systolic function with mild to moderate left ventricular dilation and coronary ectasia, and his troponins were elevated. Following Asacol discontinuation, his chest pain resolved, troponins were trending towards normal, left ventricular systolic function normalized, and coronary ectasia improved within 24 hours suggesting an Asacol-associated severe drug reaction. Mesalamine-induced cardiovascular toxicity, although rare, may represent a life-threatening disorder. Therefore, every patient presenting with acute chest pain should receive a workup to rule out this rare drug-induced disorder. |
| format | Article |
| id | doaj-art-86be151eb8804d42ab6194595e06d1d3 |
| institution | Kabale University |
| issn | 2090-6803 2090-6811 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Pediatrics |
| spelling | doaj-art-86be151eb8804d42ab6194595e06d1d32025-08-20T03:37:53ZengWileyCase Reports in Pediatrics2090-68032090-68112011-01-01201110.1155/2011/524364524364Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case ReportElimarys Perez-Colon0Gul H. Dadlani1Ivan Wilmot2Michelle Miller3Department of Pediatrics, University of South Florida, 2 Tampa General Circle, Tampa, FL 33606, USADepartment of Pediatrics, University of South Florida, 2 Tampa General Circle, Tampa, FL 33606, USAAll Children’s Hospital Heart Institute, Outpatient Care Center, 2nd Floor, 501 6th Street South Saint. Petersburg, FL 33701, USAAll Children’s Hospital Heart Institute, Outpatient Care Center, 2nd Floor, 501 6th Street South Saint. Petersburg, FL 33701, USAMesalamine-containing products are often a first-line treatment for ulcerative colitis. Severe adverse reactions to these products, including cardiovascular toxicity, are rarely seen in pediatric patients. We present a case of a 16-year-old boy with ulcerative colitis treated with Asacol, a mesalamine-containing product, who developed sudden onset chest pain after four weeks on therapy. Serial electrocardiograms showed nonspecific ST segment changes, an echocardiogram showed mildly decreased left ventricular systolic function with mild to moderate left ventricular dilation and coronary ectasia, and his troponins were elevated. Following Asacol discontinuation, his chest pain resolved, troponins were trending towards normal, left ventricular systolic function normalized, and coronary ectasia improved within 24 hours suggesting an Asacol-associated severe drug reaction. Mesalamine-induced cardiovascular toxicity, although rare, may represent a life-threatening disorder. Therefore, every patient presenting with acute chest pain should receive a workup to rule out this rare drug-induced disorder.http://dx.doi.org/10.1155/2011/524364 |
| spellingShingle | Elimarys Perez-Colon Gul H. Dadlani Ivan Wilmot Michelle Miller Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report Case Reports in Pediatrics |
| title | Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report |
| title_full | Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report |
| title_fullStr | Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report |
| title_full_unstemmed | Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report |
| title_short | Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report |
| title_sort | mesalamine induced myocarditis and coronary vasculitis in a pediatric ulcerative colitis patient a case report |
| url | http://dx.doi.org/10.1155/2011/524364 |
| work_keys_str_mv | AT elimarysperezcolon mesalamineinducedmyocarditisandcoronaryvasculitisinapediatriculcerativecolitispatientacasereport AT gulhdadlani mesalamineinducedmyocarditisandcoronaryvasculitisinapediatriculcerativecolitispatientacasereport AT ivanwilmot mesalamineinducedmyocarditisandcoronaryvasculitisinapediatriculcerativecolitispatientacasereport AT michellemiller mesalamineinducedmyocarditisandcoronaryvasculitisinapediatriculcerativecolitispatientacasereport |